中国药科大学二级教授（博导），海洋药学专业负责人，江苏省合成多肽药物发现与评价工程研究中心主任，国家药典委员会委员，国家级高层次人才项目入选者。
主编出版3部论著（《新药非临床研究与开发》、《抗肿瘤药物药理学实验指南》、《酶类药物学》），发表学术论文213篇（SCI收录81篇），申请国内专利32项（获授权24项），培养研究生160名（博士29名）。主办“第十四届中国国际多肽学术会议暨第五届亚太国际多肽学术会议”，多次受邀参加国内外学术会议报告。
多肽药物研发、全新微肽发现及机制研究、长链非编码RNA与疾病关系的分子机制。
1. 国家重大新药创制科技重大专项：一类抗肿瘤生物新药HM-3的研究与开发，主持；
2. 863高科技发展计划：多肽分子药靶发现与药物设计技术, 主持；
3. 校企合作：PEG-HM-3作为类风湿药物的许可及技术开发转让，主持；
4. 校企合作：药物新靶点及新分子发现及技术，主持；
5. 国家自然科学基金面上项目：lncRNA编码全新内源性微肽MP36促进三阴性乳腺癌发生与转移的机制研究，主持
1. Mengwei Li#, Guangxiang Liu#, Xinrong Jin, Hongqian Guo, Sarra Setrerrahmane, Xindi Xu, Tiantian Li, Yunfei Lin, Hanmei Xu*, Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma, Mol Cancer. Mol Cancer 21, 181 (2022). doi: 10.1186/s12943-022-01654-1. (IF= 41.444)
2. Li, Mengwei; Chi, Xiaowei; Wang, Ying; Setrerrahmane, Sarra; Xie, Wenwei; Xu, Hanmei*，Trends in insulin resistance: insights into mechanisms and therapeutic strategy，Signal transduction and targeted therapy，2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0.（IF=38.104）
3. Wang Y, Li M, Chen L, Bian H, Chen X, Zheng H, Yang P, Chen Q, Xu H*. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduction and Targeted Therapy. 2021;6(1):409. DOI: 10.1038/s41392-021-00805-y. (IF=38.104)
4. Peiwei Yang, Ying Wang, Zheng Yao, Xinmei Gao, Chen Liu, Xinmin Wang, Heming Wu, Xu Ding, Jialiang Hu, Bingjing Lin, Qian Li, Mengwei Li, Xin Li, Xiangying Chen, Weiyan Qi, Weiguang Li, Jianpeng Xue,* and Hanmei Xu*. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. J Am Chem Soc. 2020 Nov 4;142(44):18874-18885. doi: 10.1021/jacs.0c08538. Epub 2020 Oct 2. (IF=16.383)
5. Mengwei Li, Xin Li, Yinan Zhang, Heming Wu, Haoze Zhou, Xu Ding, Xiaomin Zhang, Xinrong Jin, Ying Wang, Xinqiang Yin, Chencheng Li, Peiwei Yang, Hanmei Xu*. Micropeptide MIAC Inhibits HNSCC Progression by Interacting with Aquaporin 2. J Am Chem Soc. 2020 Apr 8;142(14):6708-6716. doi: 10.1021/jacs.0c00706. (IF=16.383)
6. Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi, Sun Q, Zhang S, Hu J, Xu H*. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018, 11(1):102 DOI: 10.1186/s13045-018-0646-9 (IF= 23.168)
7. Erhao Zhang, Jieyi Gu and Hanmei Xu*. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018, 17(1):7. DOI: 10.1186/s12943-018-0759-3 (IF= 41.444)
8. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Zhang E, Yu L, Li M, Liu C, Hu L, Hao J, Qi W, Xu H*. Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin Cancer Res. 2018, 24(2):486-498. DOI: 10.1158/1078-0432.ccr-17-1851 (IF= 13.801)
9. Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Xu H*. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018 Mar 20;11(1):44. doi: 10.1186/s13045-018-0591-7. (IF= 23.168)
10. Setrerrahmane S, Xu H*. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153. doi: 10.1186/s12943-017-0721-9. (IF= 41.444)
